Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience.
Heinzel A, Dedic D, Galldiks N, Lohmann P, Stoffels G, Filss CP, Kocher M, Migliorini F, Dillen KNH, Geisler S, Stegmayr C, Willuweit A, Sabel M, Rapp M, Eble MJ, Piroth M, Clusmann H, Delev D, Bauer EK, Ceccon G, Dunkl V, Rosen J, Tscherpel C, Werner JM, Ruge MI, Goldbrunner R, Hampl J, Weiss Lucas C, Herrlinger U, Maurer GD, Steinbach JP, Mauler J, Worthoff WA, Neumaier BN, Lerche C, Fink GR, Shah NJ, Mottaghy FM, Langen KJ. Heinzel A, et al. Among authors: herrlinger u. Cancers (Basel). 2022 Jul 8;14(14):3336. doi: 10.3390/cancers14143336. Cancers (Basel). 2022. PMID: 35884396 Free PMC article.
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U; Neuro-Oncology Group of the German Cancer Society. Glas M, et al. Among authors: herrlinger u. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub 2011 Jun 27. Ann Neurol. 2011. PMID: 21710625 Clinical Trial.
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ. Galldiks N, et al. Among authors: herrlinger u. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25411133
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. Weller M, et al. Among authors: herrlinger u. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655102 Free article. Clinical Trial.
270 results